Remove Antibody Remove Bacterium Remove Marketing
article thumbnail

Non-vaccine nasal spray could protect against COVID-19

pharmaphorum

The programme is still in the early stages of development, but if it works in trials would provide another approach to prevent transmission of SARS-CoV-2, the virus that causes COVID-19, alongside vaccines and prophylactic antibodies.

article thumbnail

A new era in diagnostics: The growing demand for POC testing

Pharmaceutical Technology

Analysts at GlobalData predict that the market for point-of-care (POC) diagnostic devices will reach $297.6bn by 2023, a growth of almost $1bn from 2015. For strip devices, you have just a few processes for the device assembly,” says Jean-François Bauer, head of marketing and business development at Mikron Automation. “In

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Hansa gets NICE okay for Idefirix in kidney transplant patients

pharmaphorum

Around a third of patients waiting for a kidney transplant are cases as “sensitised” – meaning they have very high antibody levels to human leukocyte antigens (HLAs), which makes it more likely they will reject a donated organ. The post Hansa gets NICE okay for Idefirix in kidney transplant patients appeared first on.

article thumbnail

GSK bolsters vaccines division with $3.3bn swoop on Affinivax

pharmaphorum

billion takeover of US biotech Affinivax, buying a pneumococcal vaccine candidate that is aiming to break into a market that for years has been dominated by Pfizer’s Prevnar franchise. The biotech says this can stimulate both B cell (antibody) and T cell immune responses with a single shot. GlaxoSmithKline has agreed a $3.3

Vaccine 52
article thumbnail

Shot in the arm for Affinivax as it challenges Pfizer’s Prevnar

pharmaphorum

The shot also includes two “conserved” pneumococcal proteins – antigens that seem always to be present in the bacterium regardless of its serotype, so could potentially provide protection against an even broader range.

article thumbnail

Medicago’s Plant-Based COVID-19 Vaccine Enters Human Trials

XTalks

Interim results of the trial show that all participants developed an antibody response after two doses of the COVID-19 adjuvanted vaccine candidate. We also observed that the antibody levels were higher after vaccination than those observed in convalescent sera from people who recovered from the disease,” said Landry.

Vaccine 52
article thumbnail

Top 30 Pharma and Biotech Companies in 2023: Statistics and Trends

XTalks

Join us as we present an in-depth analysis of each company’s revenue, net income, R&D investments, core therapeutic areas, market presence and strategic collaborations. is a global pharmaceutical company, working across both developed and emerging markets. 2022 Revenue: Pfizer reported an annual revenue of $100.33 Pfizer Inc.

Sales 98